Logo

CPSH

CPS Technologies Corporation

CPSH

CPS Technologies Corporation • NASDAQ
$3.44 ▲ 2.38% (+0.08)
Market Cap $49.98 M
52w High $4.89
52w Low $1.40
Dividend Yield 0%
P/E -86
Volume 16.13K
Outstanding Shares 14.53M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $8.804M ▲ $1.226M ▲ $207.964K ▲ 2.362% ▲ $0.01 ▲ $321.565K ▲
Q2-2025 $8.079M ▲ $1.199M ▲ $103.833K ▲ 1.285% ▲ $0.007 ▲ $155.947K ▼
Q1-2025 $7.506M ▲ $1.101M ▲ $95.962K ▲ 1.278% ▲ $0.007 ▲ $294.389K ▲
Q4-2024 $5.933M ▲ $1.047M ▲ $-995.152K ▲ -16.772% ▲ $-0.069 ▲ $-1.096M ▲
Q3-2024 $4.247M $963.064K $-1.043M -24.554% $-0.072 $-1.355M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $4.288M ▲ $20.436M ▲ $5.304M ▲ $15.132M ▲
Q2-2025 $3.419M ▲ $19.37M ▲ $4.492M ▼ $14.877M ▲
Q1-2025 $2.97M ▼ $19.209M ▲ $4.493M ▲ $14.716M ▲
Q4-2024 $4.312M ▼ $18.877M ▼ $4.365M ▲ $14.512M ▼
Q3-2024 $5.71M $19.223M $3.774M $15.449M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $103.833K ▲ $649.256K ▲ $-205.138K ▼ $0 ▲ $444.118K ▲ $455.045K ▲
Q1-2025 $95.962K ▲ $-1.253M ▲ $-89.915K ▲ $-8.13K ▲ $-1.435M ▼ $-1.346M ▲
Q4-2024 $-995.153K ▲ $-1.371M ▼ $-110.387K ▲ $-11.973K ▼ $-1.324M ▲ $-1.469M ▼
Q3-2024 $-1.043M ▼ $-1.187M ▼ $-333.654K ▲ $-11.782K ▼ $-1.617M ▲ $-1.267M ▲
Q2-2024 $-954.304K $-1.048M $-1.302M $-11.593K $-2.361M $-1.6M

Five-Year Company Overview

Income Statement

Income Statement CPSH looks like a very small, niche business that usually hovers around break‑even. Sales have grown modestly over the last few years but not explosively. The company has been able to earn a positive gross profit, yet after all expenses it tends to swing between small profits and small losses. The latest year shows a move back into the red after several years of modest profitability, which underlines how sensitive results are to shifts in demand, product mix, and cost control. Overall, the income statement tells a story of a company with real technology value but still operating at a fragile profit level.

Balance Sheet

Balance Sheet The balance sheet is simple and conservative. Total assets have inched up over time, but they remain modest, reflecting a small, focused operation rather than a capital‑heavy one. The most notable strength is the absence of financial debt, which reduces financial risk and interest burden. Cash balances, however, have come down recently, lowering the financial cushion and leaving less room for prolonged weak results or big investment pushes. Equity has dipped with the recent loss, but the structure still looks straightforward and not overleveraged, just limited in scale.

Cash Flow

Cash Flow The reported data do not give much detail on cash flow, but the picture is of a company that runs close to cash break‑even, with relatively light spending on equipment and facilities. That suggests CPSH is not burning large amounts of cash, but it also may not be generating strong free cash consistently. In this kind of business, timing of customer orders, inventory builds, and government contracts can all make year‑to‑year cash flows lumpy. With a thinner cash cushion and no debt, continued careful cash management is important, especially if the company wants to scale production or pursue larger programs.

Competitive Edge

Competitive Edge CPSH operates in a narrow but strategically important corner of advanced materials, centered on its aluminum‑silicon‑carbide composites. Its strengths include proprietary manufacturing processes, a solid patent portfolio, and long‑standing relationships with demanding customers in aerospace, defense, and power electronics. These end markets have high qualification hurdles and long design cycles, which can make customers reluctant to switch suppliers once parts are designed in. That creates switching costs and a degree of stickiness. On the other hand, CPSH is tiny compared with global materials giants, and it competes against established alternatives like copper alloys and advanced ceramics. Its niche is well‑defended but not immune to budget cycles in defense, shifts in EV and infrastructure spending, and the bargaining power of larger customers.

Innovation and R&D

Innovation and R&D Innovation is one of CPSH’s clearest strengths. The company’s core AlSiC technology offers a mix of light weight, high thermal performance, and durability that is hard to replicate, and it has been proven in high‑profile missions and defense systems. Management continues to build on this base with a sizable patent portfolio, government‑funded research contracts, and partnerships such as the exclusive license for fiber‑reinforced aluminum composites. These efforts broaden the addressable markets into areas like military vehicles, motorsport, oil and gas, and advanced energy applications. Government R&D programs help fund development without heavy balance‑sheet strain, but commercial success will still depend on turning prototypes into repeat production orders and scaling manufacturing efficiently.

Summary

Overall, CPSH is a small, specialized technology company with distinctive materials know‑how and a real, defensible niche in thermal management and advanced composites. Financially, it has a clean, debt‑free balance sheet and modest resources, but profits and cash generation are thin and can swing from year to year. The recent move back into a loss highlights how exposed the company is to shifts in demand and cost structure. Strategically, its moat rests on proprietary processes, patents, and deep relationships in aerospace, defense, and power electronics, supported by ongoing R&D and government contracts. The main opportunities lie in scaling into high‑growth areas like electric vehicles, advanced energy, and defense programs, while key risks center on its small size, reliance on a relatively narrow set of markets and customers, and limited cash cushion if growth or margins stumble.

NEWS

November 10, 2025 · 4:15 PM UTC

CPS Announces Third Quarter 2025 Earnings

Read more

November 7, 2025 · 3:24 PM UTC

CPS to Host Conference Call on Third Quarter 2025 Earnings

Read more

October 29, 2025 · 4:01 PM UTC

CPS Technologies Announces Third Quarter 2025 Financial Results

Read more

October 29, 2025 · 6:45 AM UTC

European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

Read more

October 28, 2025 · 4:01 PM UTC

CPS Technologies Secures $15.5 Million Contract with Global Semiconductor Manufacturer

Read more